GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
Tessa Gargett(Centre for Cancer Biology), Michael P. Brown(South Australia Pathology), John D. Hayball(University of Adelaide), Wenbo Yu(South Australia Pathology), Malcolm K. Brenner, Eric Yvon(Houston Methodist), Susan N. Christo(The University of Melbourne), Ian D. Lewis, Gianpietro Dotti(Baylor College of Medicine)
Cited by 358
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435
The inducible caspase-9 suicide gene system as a “safety switch†to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
|Frontiers in Pharmacology|2014|390
Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease
|The Journal of Experimental Medicine|2004|390